Gelonghui, May 31 | Menovar (603538.SH) announced that recently, the company's wholly-owned subsidiary Xuancheng Minova Pharmaceutical Co., Ltd. (hereinafter referred to as “Xuancheng Minova”), the active ingredient for dagliflozin passed the technical review by the National Drug Administration Drug Evaluation Center (“CDE”), and the registration number changed to “A” status on the CDE API, pharmaceutical excipients and pharmaceutical packaging materials registration information disclosure platform.
Based on diet and exercise, this product can be used as a monotherapy to improve blood sugar control in adult patients with type 2 diabetes.